Project Grant R01HL180693
Award Date 8/1/26
Completion Date 4/30/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $721,977 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to uncover the molecular and functional organization of cardiovagal neurons that regulate heart rate through the vagus nerve. The project will map the synaptic inputs, outputs, and functional sufficiency of two distinct cardiovagal neuron subtypes—NPY2R-expressing neurons in the nucleus ambiguus and VIP-expressing neurons...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $354,982 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms driving lung fibrosis following severe viral respiratory infections. The research dissects how aberrant immune-epithelial interactions perpetuate post-viral lung damage distinct from idiopathic pulmonary fibrosis. The work focuses on three objectives: defining mechanisms that sustain...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $117,552 on January 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lymphatic endothelial alpha globin in heart failure progression. The research examines how alpha globin expression in lymphatic endothelial cells mediates cardiac remodeling and chronic inflammation in cardiometabolic heart failure. Using genetically modified mice with inducible alpha globin...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $799,256 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac protection through neuromodulation after myocardial infarction. The project, designated R01HL183128, will conduct research on the interplay between cardiac injury signals, brain integration, and peripheral sympathetic outflow following myocardial infarction. The work spans three...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...
- The National Heart, Lung, and Blood Institute awarded The Washington University $550,896 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop targeted nanotherapy for acute myocardial infarction. The project, led by Principal Investigator Jianjun Guan, will encapsulate an engineered secretome derived from naive M0 macrophages into nanoparticles for intravenous administration to simultaneously address three critical post-infarction pathologies:...
- The National Heart, Lung, and Blood Institute awarded Duke University $160,040 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 30, 2025, to investigate the ability of an injectable polypeptide scaffold to improve patient outcomes after myocardial infarction. The research focuses on partially ordered polypeptides (POPS), a biomaterial that transitions from an injectable liquid at room temperature to a physically crosslinked, porous network at body temperature. POPS...